These inhibitors are primarily used to prevent thrombosis during and after percutaneous coronary interventions (PCI) like stenting. The market has witnessed significant growth over the years owing to the rising number of PCI procedures performed annually to open blocked arteries and restore normal blood flow to the heart. P2Y12 inhibitors play an integral role in such procedures by reducing the risk of heart attacks and stent thrombosis.
The Global U.S. P2Y12 Inhibitors Market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the U.S. P2Y12 inhibitors market are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation. The growing demand for P2Y12 inhibitors is majorly driven by the significant rise in the number of PCI procedures across the country. As per estimates, over 2 million PCI procedures are performed annually in the U.S. Rising prevalence of coronary artery disease, availability of reimbursement, and growing geriatric population are some other factors augmenting the demand.
The U.S. P2Y12 Inhibitors Market Size is also witnessing substantial expansion across multiple regional markets owing to increased awareness regarding heart health, presence of advanced healthcare infrastructure, and favorable reimbursement policies. Key manufacturers are actively engaged in new product launches and strategic collaborations to strengthen their market position and capitalize on lucrative growth opportunities.
Market key trends
One of the key trends being witnessed in the U.S. P2Y12 inhibitors market is the rising popularity of generic drugs. The expiry of patents for blockbuster drugs such as clopidogrel and prasugrel has led to the market entry of various low-cost generic equivalents. This has significantly driven down treatment costs, thereby improving accessibility and spurring demand. Major companies are also focusing on developing novel oral antiplatelet agents with more specific mechanism of action, fewer drug interactions, and improved safety profiles to strengthen their product portfolios.
Porter's Analysis
Threat of new entrants: The market faces moderate threat as high capital requirements and stringent regulations act as entry barriers.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternatives.
Bargaining power of suppliers: Suppliers have moderate bargaining power owing to differentiated products.
Threat of new substitutes: The threat of substitutes is low as there are few product alternatives available.
Competitive rivalry: The competition in the market is high among the key market players.
The North America region accounted for the largest share of the U.S. P2Y12 inhibitors market in 2024. Factors such as the presence of major market players, increasing prevalence of cardiovascular diseases, rising healthcare expenditure are contributing to the large share of this region.
The Asia Pacific region is poised to grow at the fastest CAGR during the forecast period. This is attributed to factors such as growing healthcare industry, improving access to healthcare facilities, rise in disposable income, and increasing demand for advanced treatment options for various cardiovascular diseases in emerging Asia Pacific countries.
Get more insights on This Topic- U.S. P2Y12 Inhibitors Market
Comments
0 comment